|Bid||54.63 x 1100|
|Ask||54.64 x 800|
|Day's Range||54.58 - 55.38|
|52 Week Range||53.32 - 86.31|
|Beta (3Y Monthly)||0.78|
|PE Ratio (TTM)||10.26|
|Earnings Date||Jun 26, 2019 - Jul 1, 2019|
|Forward Dividend & Yield||1.76 (2.78%)|
|1y Target Est||61.43|
Walgreens partners with customer-experience specialist Narvar to add package pick-up and return service to 8,000 store locations.
Analysts at Raymond James lowered their price target on shares of CVS Health Corp. to $75 from $90 on Thursday, citing "the collapse in sentiment for the payor-PBM complex." They maintained their strong buy rating on the stock, saying they "believe the discount is unwarranted," but acknowledging "significant overhangs on the political/headline front that are unlikely to abate in the immediate term." CVS shares have fallen 20% so far this year, and peers Walgreens Boots Alliance Inc. and Rite Aid Corp. have declined by 19% and 32%, respectively. A recent rout in health stocks comes amid calls for drug price transparency and U.S. Sen. Bernie Sanders' unveiling of a new "Medicare for All" plan. The SPDR Health Care Select Sector exchange-traded fund has dipped 0.8% in the year to date, severely lagging the S&P 500 , which has gained 15.7%, and the Dow Jones Industrial Average , which has gained 13.4%.
Burger chain Carl’s Jr. will test a CBD-infused cheeseburger for one day, 4/20 of course, at one restaurant in Denver, and in time for breakfast.
Walgreens Boots Alliance, Inc. (WBA) today announced that its board of directors has declared a regular quarterly dividend of 44 cents per share, unchanged from the previous quarter and an increase of 10 percent over the year-ago quarter. Walgreens Boots Alliance and its predecessor company, Walgreen Co., have paid a dividend in 346 straight quarters (more than 86 years) and have raised the dividend for 43 consecutive years. Walgreens Boots Alliance (WBA) is the first global pharmacy-led, health and wellbeing enterprise.
The Walgreens location at 780 Waukegan Road in Deerfield is where the company "pilot and test many different services and offerings."
DEERFIELD, Ill. and SAN FRANCISCO, April 17, 2019 /PRNewswire/ -- Narvar and Walgreens are working together to provide convenient package pick-up and returns for consumers at more than 8,000 Walgreens locations offering FedEx OnSite services, empowering brands with a simple solution to meet consumer demand for more choice and convenience without investing in their own brick-and-mortar footprint. The network of locations, anchored by Walgreens, is the first offering in the Narvar Concierge suite of solutions for physical commerce, announced today. In addition to Walgreens, the Narvar Concierge network will include select Nordstrom stores.
Rite Aid Corporation (NYSE: RAD), CVS Health Corp (NYSE: CVS), and Walgreens (NASDAQ: WBA) recently announced plans to sell cannabidiol, or CBD, products in 2,500 stores across 19 states. The stores will only sell topical CBD products, such as chapstick, lotions and body sprays. Rite Aid also announced it will stop selling e-cigarettes in an attempt to address an increase in teen smokeless tobacco use.
While the broad market zooms ahead, health care stocks are being weighed down by regulatory threats even as earnings forecasts remain strong.
Oppenheimer Downgrades CVS Health Stock to 'Perform'(Continued from Prior Part)Analysts suggest “buy” Among the 27 analysts covering CVS Health (CVS) stock, 18 analysts suggest a “buy,” and nine analysts recommend a “hold.” Analysts have
Oppenheimer Downgrades CVS Health Stock to 'Perform'Near-term headwinds to set the directionOn April 15, Oppenheimer downgraded CVS Health (CVS) stock to “perform” from “outperform” and removed its price target of $85. CVS Health’s
Then this morning we learn that Amazon might be about to rollout a similar service to Spotify's free version. Now I don't know how real this Amazon foray might be. No one ever seems to want to say it but that's Amazon eating at the margins.
According to GuruFocus' list of 52-week lows, these guru stocks have reached their 52-week lows. The price of UnitedHealth Group Inc. (UNH) shares has declined to close to the 52-week low of $223.22, which is 23.3% off the 52-week high of $287.94. The company has a market cap of $214.19 billion.
When I am analyzing a company to see if it could potentially be a good long-term investment, I always research what the insiders are doing. It goes without saying that they probably have a much better idea of what is happening in the company than most analysts and they certainly know more about it than I do. I especially like to see what they are doing after their company's stock has fallen dramatically.I am not implying that there is anything illicit or illegal going on. When an insider wants to buy or sell their company's stock they can, as long as they follow very strict procedures. For instance, they have to file their intent to buy or sell with the SEC, and they are subject to "blackout periods," which are times in which they cannot trade the stock.For example, an insider may be prohibited from buying or selling the stock in the thirty days before or after the earnings release is due to be reported.InvestorPlace - Stock Market News, Stock Advice & Trading TipsWhat's more, an officer or a director of a company may decide to sell their stock for many reasons. They could need to raise money for tuitions, mortgages, weddings or even divorce settlements. But the insiders only buy for one reason: if they believe that the stock is undervalued and that it will eventually trade at a higher price where they can make a profit. * 7 Mid-Cap Stocks to Find the Market's Sweet Spot The following stocks have experienced such insider buying, and as such, are worthy of further inspection: EQT Corp (EQT) Click to Enlarge EQT Corp. (NYSE:EQT, $21.61) deals with natural gas in the Appalachian area. You may have never heard of EQT corporation, but you have probably used their products, as it's the largest producer of natural gas in the United States.Insider buying at the EQT Corporation has been prolific. The President, Robert McNally, bought almost 21,000 shares on March 29 at an average price of $20.80. He spent $200,000. The Executive Vice President, Erin Centofanti, bought almost 8,000 shares on March 29 at $20.83. Sue Smith, the CFO, paid $19.75 for 6,000 shares on March 14.Back in February Jonathon Lushko, the General Counsel and a Senior VP of the company, purchased almost 8,000 shares on the open market at an average price of $19.04. That is an investment of almost $150,000. In addition, the Senior VP of Human Resources, David Smith, invested more than $300,000 when he purchased 16,800 shares of the stock at an average price of $19.06.It is always interesting to see if and when the insiders buy their company stock after it has sold off significantly. In this case, the price of EQT has fallen about 50% in less than a year. This could be the reason why these insiders decided to invest. The stock is currently trading around $21.61, so they have already profited nicely.The analysts on Wall Street seem to like this stock as well. According to MarketWatch, twenty firms follow it on a research basis. Two of them have it rated as overweight, eleven have a buy rating on it, six rate it as holds and there's just one sell recommendation. The average target price is $25.40, which is about 20% higher than where it is currently trading. RumbleOn (RMBL) Click to Enlarge RumbleOn, Inc. (NASDAQ:RMBL, $5.60) is an e-commerce platform that is designed to help consumers and dealers finance, buy and sell used cars.Denmar Dixon is a member of the Board of Directors of RumbleOn. Mr. Dixon purchased 50,000 shares at $4.76 in early April. He also made considerable purchases early last year before the stock rallied. Back then, it was trading around the same levels that it currently is.The stock more than doubled when it traded above $10 in September and October. Mr. Dixon must have been feeling pretty good. But then it went into freefall and lost more than 50% of its value by December. * 10 Stocks That Are Screaming Buys Right Now This company is followed on a research basis by six companies. The average rating is a buy and the average target price is $9.90, which is more than 40% higher than where it is currently trading. Endologix (ELGX) Click to Enlarge Endologix, Inc. (NASDAQ:ELGX, $6.99) performs research and development and manufactures devices that treat aortic diseases. Its portfolio of products includes AFX Endovascular AAA System, Nellix and Ovation.On April 3, it was announced that the CEO, John Onopchenko, invested $200,000 when he purchased just over 30,000 shares. This increased his personal holdings in the stock by almost 40%. The CFO, Vaseem Mahboob, invested $100,000 of his personal money when he acquired 15,000 shares. In addition, two of the company's directors bought and additional 25,000 shares. These shares were all purchased at an average price of $6.61.Endologix has lost more than 90% of its value over the past year. They have recently announced that they are going to restructure their debt. This could be a good thing, or it could be a sign of desperation. The insider buying may mean that the insiders think that the restructuring will work.According to MarketWatch, nine firms follow this stock on a research basis. One has a buy rating on it, one has a sell rating and the other nine consider it a hold. The average target price is $10.30, which is significantly higher than where it is currently trading. This makes me wonder why seven firms have a hold on a stock that they feel is undervalued by 35%. Walgreens (WBA) Click to Enlarge You've probably been to Walgreens (NYSE:WBA, $54.69). It's one of the largest pharmacies in the country, with retail and pharmacy operations both domestically and on an international stage. The company was founded in 1901 and is headquartered in Deerfield, IL.Co-Chief Operating Officer Ms. Omella Barra may think that the recent selling in WBA is overdone. She invested nearly $1 million of her own money when she purchased 18,000 shares at an average price of $54.50 on April 3.WBA has had some issues lately. The company has sold off considerably because the two most recent earnings releases disappointed investors. The stock has fallen about 35% since November and it is trading at the lowest level that it has been at since 2014. Time will tell if there will be more insider buying. * The 7 Best Long-Term Stocks for 2019 And Beyond This company is widely followed on Wall Street. According to Marketwatch.com, 26 firms cover it. The average analyst rating is a hold and the average price target is $62.50. It is currently trading just under $55. Chaparral Energy (CHAP) Click to Enlarge Chaparral Energy, Inc. (NYSE:CHAP, $5.58) is in the natural gas and oil exploration and production (E&P) business. Specifically, CHAP makes its money on deposits of Stack, Meramec and Osage, Oswego and Woodford located in Oklahoma and the Texas Panhandle. Founded by Mark A. Fischer and Charles A. Fischer in April 1988, Chaparral Energy is headquartered in Oklahoma City, OK.The CEO of the company, K. Earl Reynolds, purchased 7,100 shares of CHAP on March 29th at an average price of $4.64. A large institutional holder, Strategic Value Partners, also recently acquired 900,000 shares at a price of $4.45.The stock has fallen by more than 75% over the past year. Mr. Reynolds and the portfolio managers at Strategic Value Partners must believe that the stock is very attractive at these prices.Wall Street likes this stock as well. It is followed by four firms that follow the company on a research basis. The average rating is a buy and the average target price is $18.38. That is more than 300% higher than where it is currently trading.As of this writing, Mark Putrino did not hold any positions in the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Internet Stocks to Watch * 7 AI Stocks to Watch with Strong Long-Term Narratives * 10 Dow Jones Stocks Holding the Blue Chip Index Back Compare Brokers The post 5 Stocks to Profit From (Legal) Insider Buying Signals appeared first on InvestorPlace.
from outperform to perform on Monday, citing drug pricing headwinds and the company's unfavorable exposure to the managed-care business. Oppenheimer removed its $85 price target for CVS, which was 64% above the stock's closing price on Friday. "We are looking to reset the bar on our CVS rating, as we view it as more of a long-term opportunity given the potential timeline to execute on its strategy and the near-term legacy business challenges," the analysts wrote.
April started poorly for Walgreens Boots Alliance (NASDAQ: WBA). A weak second-quarter earnings report sent Walgreens stock down 12.8% on April 2. With a downtrend very clearly in place, why should investors even consider WBA stock after the plunge?Source: Mike Mozart via FlickrWalgreens reported non-GAAP earnings of $1.64 as revenue grew 4.6% to $34.53 billion. A confluence of negative headwinds hit the company's bottom line. Higher reimbursement pressures, lower generic deflation, lower brand inflation and weak performance from restructuring programs led to the poor results. * 7 Marijuana Companies: Which Pot Stocks Should You Buy? Markets now know why Walgreens, along with CVS (NYSE: CVS) and Rite Aid (NYSE: RAD) fell ahead of the results report. Markets even sold off health care plan stocks like Cigna (NYSE: CI) and Humana (NYSE: HUM) in 2019: there are significant market-wide headwinds.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Long-Term Growth and Walgreens StockWalgreens has four strategic priorities aimed at delivering sustainable, long-term growth. It is accelerating the company's digital footprint, transforming its approach to retail, creating neighborhood health destinations, and implementing a revamped cost management program.This jargon on cost reduction will not mean much to the shareholder who just lost 12.8%.To stabilize the business as reimbursement pressures worsen, Walgreens must improve same-store sales. The near-term problems in achieving growth here are the acquired Rite Aid stores. Sales grew 7.3% and organic sales grew 1.6% but adjusted growth profit declined a substantial 3.5% in the quarter. Pharmacy and retail both fell. Gross margin from Pharmacy fell 260 basis points.A 6.8% drop in SG&A spend, along with cost savings initiatives ahead may slow the weakening operating income, which fell 11.9% in the second quarter. Opportunity and Walgreens StockA weaker cough, cold, and flu season added to Walgreens' woes but could create an opportunity for value investors. Since results were so weak, Walgreens could move up from here if management moves swiftly to balance its operating expenses against the higher reimbursement pressure.Digitization will help Walgreens increase its efficiency but it needs more than that. Still, bringing in the Microsoft (NASDAQ: MSFT) Teams to consolidate its internal digital team under a Chief Digital Officer will improve back-office efficiency.Walgreens restructured management such that there are two teams in development and delivery. One accomplishment is that its 5-star rated app has 55 million downloads. Another is it has 85 million active Balance Rewards members. The drug store clearly has the potential to reach out to its customer base through the mobile app. What is not clear yet is how much more business the app will bring for Walgreens. Near-term OutlookThe weak current third quarter for Walgreens will follow with improvements in Q4. While investors are disturbed by management's realistic goal-setting of mid-to-high single-digit growth, the reset in expectations creates an entry point for value investors.Plus, with the company working to offset the generic impact by 50% - 60%, profit margins may start to stabilize. Overall, it plans to cut costs by $1.5 billion. That is a substantial number and will benefit the company's long-term health.Walgreens will also shift its resources towards growing its Health & Beauty segment where it is confident that it can win an already very attractive business. The Bottom Line on Walgreens StockThe analyst positional changes are mixed. According to Tipranks, one analyst called WBA stock a "sell" while six have a "hold" and two analysts have a "buy." The average price target is $61 a share, which suggests the stock has an upside of 11%.Patient investors may want to wait for the selling-pressure to ease for a few days. Walgreens is already trading at a discount but this could widen. Still, even though drug store stocks are out of favor, Walgreens is the strongest of the available picks.Disclosure: As of this writing, the author did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Internet Stocks to Watch * 7 AI Stocks to Watch with Strong Long-Term Narratives * 10 Dow Jones Stocks Holding the Blue Chip Index Back Compare Brokers The post There's a Buy the Dip Opportunity in Walgreens Stock but It Isn't Now appeared first on InvestorPlace.
There are fundamental problems for brick-and-mortar pharmacies that the companies may be unable to solve.
Rite Aid (RAD) posts narrower-than-expected loss in fourth-quarter fiscal 2019. Moreover, it issues a soft outlook for fiscal 2020.
Everything you think you know about REITs? Forget it before you put Realty Income (NYSE:O) under the microscope. Realty Income stock is far less subject changes in interest rates than most investors care to believe, and much more of a sentiment-driven trading vehicle than most investors care to concede.Source: Yuriy Trubitsyn via UnsplashTo that end, now would be a good time to take profits on Realty Income stock if you're long, and if you're daring enough, perhaps even short it.That's a counterintuitive strategy for students of what makes the market tick. Rising rates are supposed to work against real estate investment trusts by increasing the cost of capital, while falling or stagnant interest rates help make and keep money cheap.InvestorPlace - Stock Market News, Stock Advice & Trading TipsRight now the Federal Reserve seems mostly ready to let rates stand pat, with some whispers of a rate-cut circulating in the market's ether. That's supposed to be good for REITs.In the real world though, we've rarely seen that relationship hold up. In the real world, Realty Income is uncomfortably vulnerable here. * 7 AI Stocks to Watch with Strong Long-Term Narratives Right REITOn paper, it shouldn't have happened. But it did. Against a backdrop of steady rate increases over the course of last year, Realty Income stock rallied from an early-2018 low near $47 to a high-near $74 just a couple of weeks ago. That's a 57% gain.Why didn't the Fed's four rate-hikes deflate the rally? Because there's far more to the matter than mere interest rates. Many investors get the market's easy stuff. Earnings growth is good. Bear markets are bad. Diversity staves off volatility.Not all investors can fully process multi-faceted and sometimes arbitrary pressures on a stock though. Realty Income is one of those names with a lot of moving parts.Chief among them is the fact that it rents space to some of the world's most recognized and reliable companies. Its top tenants include Walgreens Boots Alliance (NASDAQ:WBA), FedEx (NYSE:FDX) and Dollar General (NYSE:DG). Those companies may ebb and flow, but for the most part they're not going anyway. And, unlike 2008's subprime mortgage meltdown, the underlying assets that make up realty income aren't quite as subject to an implosion as on over-mortgaged home is.If nothing else, Realty Income has been and always will be at least reasonably dependable.There's a much bigger (albeit related) tailwind that's boosted the O stock price far more than rising rates have worked against it, however. That is, the solid economic growth that inspired last year's quartet of interest rate increases in the first place. Wrong TimeWhile the tariff war, in addition to a long-lived government shutdown, has dialed back the impressive and consistent GDP growth, it still is growth.After soaring to a pace of more than 2.0% in the latter half of 2017 and racing to annualized growth of 4.2% in the second quarter of 2018, Corporate America was humming. Corporate profits reached record levels during the third quarter of last year, prompting investment in more growth and the leasing of new profit centers.Realty Income had no trouble finding and keeping consumer-facing tenants, boasting an occupancy rate of 98.6%. It was able to raise its average rental prices as well. Economic strength mattered more than rising interest rates, pushing shares upward.The backdrop is changing now though, for fundamental as well as psychological reasons. Fundamentally, the economy may still be on a reasonably firm footing, but growth rates are undeniably slowing. International trade friction is very real, and the year-over-year comps translate into tougher comparisons.In the meantime, Q4's GDP growth was pared back to match multi-year lows near 2.2%. It's not bad, but it's certainly not red hot. There's also no particular reason to suspect growth will turn red-hot again anytime soon.Psychologically, investors may be starting to realize they got a little ahead of themselves with Realty Income last year. It's not the first time it's happened either. The weekly chart tells the tale. This REIT is really good at rallying for prolonged periods, but that rally is always unwound in a big way.The relative slowdown in the very economic growth that catapulted Realty Income stock last year, will serve as the bearish fodder the market needs now that shares are uncomfortably overextended. Bottom Line for Realty Income StockThe great irony is, none of the stock's past rises and falls nor any of its future gains and losses will actually be a full reflection of the REIT's results. Revenue, operating income and funds from operations are all quite steady, and the real estate investment trust recently announced its 101st dividend increase.It's been a picture of consistency and reliability. The big swings of the O stock price are largely prompted by traders' ever-changing perception.Nevertheless, if that's the game most investors are playing, then that's the game would-be buyers have to play too. Anyone interested may want to let some of the froth burn off first. It could take a while to gauge the true strength of the economy here anyway.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * FAANNG Stocks, Ranked From Cheapest to Most Expensive * 7 Stocks With a Lot on the Line This Earnings Season * 7 Marijuana Companies: Which Pot Stocks Should You Buy? Compare Brokers The post If You Own Realty Income Stock, It's Time to Take Your Profits appeared first on InvestorPlace.
U.S. Sen. Bernie Sanders of Vermont unveiled a new version of his “Medicare-for-all” plan on Wednesday, sparking renewed discussion about what such a plan would cost and how it might affect the many different stakeholders in the health care space. Sanders’s proposal would create a single-payer health care system where a government-run plan guaranteeing coverage for all would replace the current job-based and individual private health insurance system. This new version of Sanders’s Medicare-for-all plan comes at a time when the health-care sector has been significantly underperforming the S&P 500 (SPX) .The Health Care Select Sector SPDR Fund ETF (XLV) has gained 4.4% in the year to date, while the S&P 500 has gained 15%.
On April 10, the two companies announced plans to build primary care clinics at five Walgreens locations in Houston.
Shares of discount retailer Fred's Inc. jumped 5.7% in Thursday premarket trading after it said it will start liquidation sales at 159 stores that it is shuttering, part of a strategy to turn around the struggling company. The stores that are scheduled to shutter had expiring leases or limited obligations left on their leases, according to a statement from Fred's Chief Executive Joseph Anto. All of the stores should be closed by May 2019, leaving 398 stores in the company's fleet. Fred's also continues to pursue opportunities to sell its remaining pharmacy assets. In September, the company announced a deal to sell pharmacy assets at 179 stores in 10 southeastern states to Walgreens Boots Alliance Inc. , a deal that closed in the fourth quarter. Fred's has hired PJ Solomon to review all strategic alternatives, with no guarantee of any further action. Fred's shares are up 10.6% for 2019 so far while the S&P 500 index has gained 15.2% for the period.
Joey Agree, Agree Realty CEO, joins 'Fast Money Halftime Report' to discuss real estate setting another record in REITs.
Rite Aid announced plans sell CBD products in more than 200 of its drugstores across Washington State and Oregon. Yahoo Finance's Brian Cheung, Jared Blikre and Ines Ferre join Seana Smith on 'The Ticker' to discuss the news.
Measles outbreak has reached its second highest level in 20 years, according to the CDC, and it's costing the health care system money. Yahoo Finance's Zack Guzman and Kristin Myers are joined by Glenn Hall, Dow Jones Newswire Global Chief Editor, to discuss.